Introduction
Hyperlipidaemia is now an established major factor for the development of coronary artery disease.I Considerable attention has been focused on levels of low and high density lipoproteins (LDL. HDL) and the apolipoproteins as risk factor determinants.r"
Recently. there has been a considerable resurgence of interest in lipoprotein (a) (Lp(a». since there is strong evidence th~t the level of circulating Lp(a) represents an independent risk factor for coronary vascular disease with possibly greater predictive potential h I , . t it 5 6 than the ot er ipoprotem rai S.·· Biochemistry and metabolism Lipoprotein (a) possesses many similarities to LDL in its physical and chemical properties. The major protein constituent of both lipoproteins is apolipoprotein BlOO (apo Bl(0). however. Lp(a) is unique in that it contains a highly glycosylated protein responsible for the (a) epitope. This apo (a) is attached to apo Bl00 by disulphide bridges. Due to this additional protein moiety Lp(a) migrates with prebeta mobility on agarose gel electrophoresis and has a density distribution of 1·05~J.l20 glmL. 7 -9 It has been demonstrated that Lp(a) exhibits considerable heterogeneity with respect to protein and lipid composition both inter-and intraindividually. Additionally heterogeneity in the size of apolipoprotein (a) exists. Three different species have been described. either smaller, equal or larger than apo Bloo in molecular weight.III Despite similarities between Lp(a) and LDL. Lp(a) is not a metabolic product of very I~w density lipoprotein (VLDL). LDL or chylomicrons and appears to be synthesised as a separate Jipoprotein.!': 12 Furthermore. serum Lp(a) is Correspondence: Dr R Houlston. not converted to other lipoproteins. However. the apo(a) antigen has be~n de\~cted in V:LDã nd chylomicron-like particles. . Some kinetic parameters of Lp(a) have been reported showing similarities between Lp(a) and LDL. The mean fractional catabolic rate (FCR) and the percentage average of the total pool were equal or only slightly different." It has been shown that drugs and dietary manipulations that alter LDL and apo B levels do not appear to affect levels of Lp(a). 15. 16 Thus. in spite of the close structural and kinetic resemblance the two lipoproteins appear to be under entirely separate metabolic control.
To date the mechanism of Lp(a) catabolism has not been elucidated. Since the main apolipoprotein of Lp(a) is apo '8100 it has been proposed that binding of Lp(a) to cell surface receptors prior to internalisation could play a similar role as for the LDL. Although reduced Lp(a) is specifically bound with high affinity to the same receptors on human fibroblasts as LDL. native Lp(a) is a much poorer ligand for the LDL-receptor. 9 , 14 However. some workers have been able to show that the disulphide bonds between apo Band apo (a) can be cleaved under physiological conditions." Whilst experiments indicate that the Lp(a) may be taken up by the LDL receptor mediated pathway in vitro the fact that LDL plasma concentrations far exceed those of Lp(a) and that the FCR reported for Lp(a) in an individual wi~h homozygous familial hypercholesterolaemia was only marginally reduced as compared with normal individuals.l" suggests that the LDL receptor pathway does not provide a significant route for Lp(a) catabolism.
Lp(a) determinations
Originally in clinical studies Lp(a) levels we.re determined by lipoprotein electrophoresis, however this technique which is at best semiquantitative. has largely been superceded by quantitative immunologically based ones. Radioimmunoassay.P: 17 immunoelectrophoresis'! and radial immunodiffusion (RID)lll have all been used. Antisera against Lp(a) has been harvested from a number of different animal species, goat, horse and rabbit. Lp(a) for immunisation or use as standard material has been generally isolated from human plasma by ultracentrifugation and purified by gel filtration. In order to obtain antisera monospecific for the Lp(a) antigen, anti-Lp(a) sera is absorbed with isolated LDL followed by low speed centrifugation. II. 19-2\ Problems relating to stability of such prepared Lp(a) as a reference standard and a lrr.oghilisation procedure have been described. ' Commercial antiserum, standards, and premade RID plates are available (Immuno Ltd, Artie House, Dunton Green, Kent, UK). The shelf lifes of reconstituted standard and opened plates are given as 2 and 4 weeks respectively.
Clinical significance
The suggestion that Lp(a) might be a risk factor for cardiovascular disease dates from the observations of Dahlen et al. in 1972 who found an increased frequency of an extra pre-betaband on lipoprotein electrophoresis in individuals with angina pectoris, as compared with controls.P' There have, subsequently, been a number of similar studies of a cross-sectional nature producing further evidence for the involvement of Lp(a) levels as a risk factor for atherosclerosts.F: [25] [26] [27] [28] [29] [30] [31] using both qualitative and quantitative techniques for Lp(a) analysis. In each a significant difference between patients and controls was observed, although it would appear that the tendency for association is stronger in younger cases. Lp(a) levels greater than 30 mg/dL appear to be associated with increased risk." Relative risks attributable to Lp(a) have been calculated and range from a rather surprisingly high 3·6 to a low 1·6. This may be due in part to variation in age plus possible laboratory drift where patients and controls have not been studied simultaneously. Additionally, an association between levels of Lp(a) has been shown to be a risk factor for cervical atherosclerosisf and cerebral infarction. III The question of whether Lp( a) represents an independent risk factor for myocardial infarction has been examined. In one study, levels appeared to be interdependent from other lipoprotein measurements, including apo B. IS This is in keeping with the observation that they are under separate metabolic control. II, 12 There is, at present, little documented prevalence data which is essential to an understanding of the interacting role of Lp(a) in ethnic groups, and between sexes. One study of black and white men has demonstrated a near twofold increase in Lp(a) levels in blacks as compared to white individuals, I') this clearly does not help to explain the protection of the cardiovascular system enjoyed by blacks. Furthermore, in both black and white men there was a very weak, but significant association between Lp(a) levels and apo B levels. The disparity between this finding and that of others15 is likely to have arisen from population differences. However, even accepting this finding, the conclusion was that the major portion of risk generated from levels of apo Band Lp(a) were imparted independently.
The role of Lp(a) in atherogenesis
There are several reasons to believe that the association between Lp(a) and coronary heart disease may be causal in nature. Lp(a) is minimally influenced by environmental circumstances, and there has generally been a failure to demonstrate correlation with other lipoprotein parameters as confounding effects. Furthermore. Lp(a) possesses strong similarities to atherogenic LOL and has been detected in atheromatous plaques."
The possible atherogenic mechanisms of Lp(a) are still speculative. Clearly. Lp(a) is not simply contributing to the pool of atherogenic LOL since patients with low and high Lp(a) levels may have similar LOL levels. 34 One possible explanation for its atherogenicity could be enhanced interaction with macrophages. It is known that the size of the negative charge of lipoproteins influences their uptake as has been demonstrated with acetyl and malondialdehyde derivates of LOL. 35 The high sialic acid content of Lp(a) which is four to sixfold greater than that of LOL contributes significantly to the negative charge of native Lp(a).3t> Another suggestion is that whilst LOL-receptor mediated uptake occurs, non-receptor uptake has been reported and when aggregated Lp(a) particles have been presented to macrophages, cholesterol ester formation has been observed. Lp(a) has been shown to be easily aggregated ill vitro by lysolecithin a reaction product generated by phospholipase A2 and lecithin cholesterol acyltransferase.:" Of considerable interest is the finding that there is striking homology between a partial amino acid sequence of Lp(a) and that of plasminogen.I" Furthermore, it has been shown that the cONA sequence for apo(a) is homologous to plasminogen" The Kringle-domains of plasminogen have been implicated in fibrin binding to endothelial cells and similar domains have been identified within apo(a) together with a region of serine protease activity. It is thus conceivable that apo(a) could, therefore, direct Lp(a) particles to sites of fibrin deposition (vascular injury) and thus provide a concentrated substrate for the acetyl LOL receptors of macrophages.
Genetics of Lp(a)
Levels of Lp(a) in the plasma vary considerably ranging from barely detectable to nearly 100 mgldL,20.40 and there seems little doubt that Lp(a) represents a quantitative genetic trait. Given our current knowledge of Lp(a) any genetic model proposed should be able to cope with the constraints of varying levels and heterogeneity of the protein phenotype. Originally, it was proposed that this was under single gene control, by Berg in 1%3 20 who first described Lp(a). However, this was later questioned on the basis of the sensitivity of the original immunological methods as individuals who were typed as negative were subsequently shown to have low levels. Polygenic models have been proposed, but more recently the original model with the proviso that part of the variance may be controlled by polygenes and or that the major locus could have more than two alleles has been suggested. 5 A novel~roposal has been offered by Utermann et al. I Lp(a) phenotypes were described on the basis of their selective mobilities on SOSpolyacylamide gels and these were significantly associatedwith serum Lp( a) concentrations. This has led to the suggestion that the same gene locus was involved in determining Lp(a) glycoprotein phenotypes and Lp(a) concentrations. Family pedigree studies were compatible with this concept of a series of autosomal alleles at a single locus. Such a situation is analogous to that of apolipoprotein E phenotypes.
Drug modification of Lp(a) levels
In the future it is conceivable that there may be the need to reduce levels of Lp(a) therapeutically. Whilst levels have been shown to be unaffected by the bile sequestrant cholestyramine," bezafibrate," oestrogen therapyIS or clofibrate'P; niacin, neomycin and the anabolic steroid stanozolol have been shown to produce a reduction in circulating Lp(a).
These observations are drawn from two studies, one employing neomycin and niacin in 14primary Type II hyperlipidaemic individuals, in these a 48% reduction was observed in Lp( a) levels when both drugs were used in conjunction.f However, the response was highly variable with those patients exhibiting very low levels prior to drug treatment having the smallest reduction. A 23% reduction in Lp(a) resulted from the use of the anabolic steroid stanozolol in 10 normolipaemic postmenopausal individuals.P however this reduction was paralleled by a decrease in HOL levels particularly of the HD~subclass suggesting that considerable caution be exercised if this is to be used in future studies as a therapeutic agent.
Conclusion
Overall, the evidence implicates Lp(a) as an independent risk factor for atheroma. Since levels are independent of age.!" 44 the usefulness of Lp(a) in the determination of long-term risk of cardiovascular disease may be a real possibility. However, at present there is clearly a need for a long-term prospective study to substantiate this.
The advent of recombinant DNA technology with the cloning the eDNA for Lp(a)39 will undoubtedly lead to a fuller understanding of Lp(a). Firstly, examination of tissue levels of messenger RNA coding for Lp(a) will establish sites of synthesis and secondly the use of restriction fragment length polymorphisms (RFLPs) will help to clarify the genetics with the possibility of identifying high risk individuals.
